Table 3.
Correlations of YAP1 mRNA expression and clinical and molecular parameters of the gene expression dataset (n=1107)
| |
All patients, n=1107 |
|
ER+ patients, n=700 |
|
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| |
YAP1 mRNA Quartiles |
|
YAP1 mRNA Quartiles |
|
||||||
| |
Q1 |
Q2 |
Q3 |
Q4 |
|
Q1 |
Q2 |
Q3 |
Q4 |
|
| Variable | n=277 (%) | n=276 (%) | n=277 (%) | n=277 (%) | p-value | n=175 (%) | n=175 (%) | n=175 (%) | n=175 (%) | p-value |
| NHG |
|
|
|
|
|
|
|
|
|
|
| I |
29 (15) |
43 (24) |
46 (24) |
49 (24) |
|
17 (15) |
34 (31) |
33 (28) |
38 (30) |
|
| II |
94 (47) |
79 (43) |
77 (40) |
80 (38) |
|
60 (51) |
48 (44) |
54 (46) |
48 (37) |
|
| III |
77 (38) |
61 (33) |
69 (36) |
80 (38) |
0.355a |
40 (34) |
27 (25) |
31 (26) |
42 (33) |
0.165a |
| Lymph node status |
|
|
|
|
|
|
|
|
|
|
| Negative |
187 (81) |
207 (87) |
194 (80) |
192 (85) |
|
138 (80) |
155 (89) |
139 (81) |
138 (79) |
|
| Positive |
44 (19) |
31 (13) |
47 (20) |
35 (15) |
0.715b |
34 (20) |
20 (11) |
32 (19) |
36 (21) |
0.433b |
| Tumour size |
|
|
|
|
|
|
|
|
|
|
| <20 mm |
78 (48) |
85 (54) |
93 (54) |
82 (48) |
|
55 (45) |
59 (52) |
72 (59) |
76 (56) |
|
| ≥20 mm |
86 (52) |
72 (46) |
78 (46) |
88 (52) |
0.917b |
66 (55) |
54 (48) |
50 (41) |
59 (44) |
0.056b |
| ERα |
|
|
|
|
|
|
|
|
|
|
| <10% |
44 (19) |
57 (24) |
56 (23) |
82 (36) |
|
- |
- |
- |
- |
|
| ≥10% |
188 (81) |
180 (76) |
187 (77) |
145 (64) |
<0.001b |
- |
- |
- |
- |
|
| PgR Quartiles |
|
|
|
|
|
|
|
|
|
|
| Q1 |
66 (24) |
62 (22) |
60 (22) |
89 (32) |
|
51 (29) |
45 (26) |
36 (21) |
43 (25) |
|
| Q2 |
82 (30) |
76 (28) |
60 (22) |
59 (21) |
|
49 (28) |
48 (27) |
41 (23) |
37 (21) |
|
| Q3 |
76 (27) |
70 (25) |
71 (25) |
60 (22) |
|
40 (23) |
43 (25) |
48 (27) |
44 (25) |
|
| Q4 |
53 (19) |
68 (25) |
86 (31) |
69 (25) |
0.836a |
35 (20) |
39 (22) |
50 (29) |
51 (29) |
0.011a |
| Cyclin D1 Quartiles |
|
|
|
|
|
|
|
|
|
|
| Q1 |
57 (20) |
73 (26) |
66 (24) |
81 (29) |
|
31 (18) |
45 (26) |
51 (29) |
48 (27) |
|
| Q2 |
41 (15) |
63 (23) |
87 (31) |
85 (31) |
|
26 (15) |
47 (27) |
53 (30) |
49 (28) |
|
| Q3 |
69 (25) |
69 (25) |
78 (28) |
61 (22) |
|
47 (27) |
33 (19) |
44 (25) |
51 (29) |
|
| Q4 | 110 (40) | 71 (26) | 46 (17) | 50 (18) | <0.001a | 71 (41) | 50 (28) | 27 (16) | 27 (16) | <0.001a |
NHG=Nottingham Histological Grade, ER=Estrogen receptor, PgR=Progesterone receptor.
aSpearman´s rank correlation.
bMann–Whitney U test.